Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Tempus AI, Inc. Class A Common Stock(TEM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TEM
09/17/2026: TEM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Tempus AI is an innovative health technology company that operates at the intersection of AI and precision medicine. The firm is well-regarded for its massive, multi-modal clinical data library, which serves as a powerful resource for both clinical diagnostics and pharmaceutical drug discovery. While Tempus shows significant growth potential and a unique, data-driven value proposition, it faces risks related to intense competition and the challenges of integrating AI into complex medical workflows. The company is currently prioritizing scaling operations over short-term profitability. It is a suitable consideration for growth-oriented investors who are comfortable with the inherent volatility of the health-tech sector and wish to monitor long-term clinical adoption milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Tempus offers exposure to the rapidly growing intersection of AI and precision medicine. |
| Momentum investor | Strong fit while signal remains positive | The company captures high interest due to its alignment with AI thematic trends. |
| Value investor | Weak fit | The company is currently in an aggressive growth phase with significant losses. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes reinvestment. |
| Low-risk investor | Weak fit | The stock is subject to significant volatility inherent to high-growth tech firms. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on AI market sentiment. |
| Valuation risk | Medium / high | Current market valuation relies heavily on long-term growth expectations. |
| Competition risk (AI/Diagnostic) | High | Increased competition could compress margins for testing and data services. |
| Business quality | Medium | While the platform is robust, the company is still achieving sustainable profitability. |
| Dividend income | Low / none | No income stream is provided to shareholders. |
| Execution risk | Medium / high | Success depends on the complex integration of AI into established medical practices. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -49.77% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.50B USD | Price to earnings Ratio - | 1Y Target Price 68.18 |
Price to earnings Ratio - | 1Y Target Price 68.18 | ||
Volume (30-day avg) 7.4M shares | Beta 3.72 | 52 Weeks Range 40.77 - 104.32 | Updated Date 09/18/2026 |
52 Weeks Range 40.77 - 104.32 | Updated Date 09/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Genomics and Diagnostics | Clinical genomic testing and patient diagnostic services. | The company earns revenue by providing essential medical testing for cancer patients. |
| Data and Pharma Services | Collaborations with pharma for drug R&D and licensing of proprietary datasets. | Tempus gets paid to share insights from its database to help drug companies invent new therapies faster. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13.33B | Price to Sales(TTM) 10.13 |
Enterprise Value 13.33B | Price to Sales(TTM) 10.13 | ||
Enterprise Value to Revenue 9.31 | Enterprise Value to EBITDA - | Shares Outstanding 175.39M | Shares Floating 115.90M |
Shares Outstanding 175.39M | Shares Floating 115.90M | ||
Percent Insiders 36.78 | Percent Institutions 59.25 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquarters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky J.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3800 | Website https://www.tempus.com |
Full time employees 3800 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.